NDAINHALATIONGAS
Approved
May 2014
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MEDICAL AIR, USP (medical air) by American Gene Technologies. Approved for idiopathic pulmonary fibrosis. First approved in 2014.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEDICAL AIR, USP is an inhaled gas therapy approved for idiopathic pulmonary fibrosis (IPF), a progressive lung disease with limited treatment options. The product is administered via inhalation as a gas formulation. No specific mechanism of action has been disclosed in available data.
Peak
Peak lifecycle stage suggests mature commercial operations with established market presence; team size and hiring likely stable to declining.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on MEDICAL AIR, USP at American Gene Technologies? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.